A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
Gregory L. Moore(Xencor (United States)), Michael Hedvat(Xencor (United States))
Cited by 17
Related Papers
No related papers found
Powered by citation graph analysis